Detalhes bibliográficos
| Ano de defesa: |
2024 |
| Autor(a) principal: |
SILVA, Fernanda Teixeira
 |
| Orientador(a): |
SALGADO FILHO, Natalino
|
| Banca de defesa: |
SALGADO FILHO, Natalino
,
FONTENELE, Andrea Martins Melo
,
MONTEIRO, Sally Cristina Moutinho
,
GOMES, Bruno Alexandre Quadros
,
GALATO, Dayani
|
| Tipo de documento: |
Dissertação
|
| Tipo de acesso: |
Acesso aberto |
| Idioma: |
por |
| Instituição de defesa: |
Universidade Federal do Maranhão
|
| Programa de Pós-Graduação: |
PROGRAMA DE PÓS-GRADUAÇÃO EM SAÚDE DO ADULTO
|
| Departamento: |
DEPARTAMENTO DE MEDICINA II/CCBS
|
| País: |
Brasil
|
| Palavras-chave em Português: |
|
| Palavras-chave em Inglês: |
|
| Área do conhecimento CNPq: |
|
| Link de acesso: |
https://tedebc.ufma.br/jspui/handle/tede/5279
|
Resumo: |
INTRODUCTION: Chronic Kidney Disease (CKD) is a public health problem, characterized by the progressive loss of nephron function with consequent loss of the ability to filter blood and maintain homeostasis. The treatment of CKD is complex and depends on the severity of the disease. OBJECTIVES: The general objective of this study was to evaluate the pharmacological profile of drugs prescribed to patients with non-dialysis chronic kidney disease. METHODOLOGY: This was a descriptive, cross- sectional study of 100 patients with CKD undergoing non-dialysis treatment. The drugs were classified according to the Anatomical Therapeutic Chemical (ATC). Drug interactions were assessed using the Lexicomp - Up to Date® tool. Drug-Related Problems (DRPs) were classified and pharmaceutical interventions carried out. The Beers Criteria were used to identify inappropriate medicines for the elderly. The analysis was carried out using descriptive and analytical statistics. RESULTS: 52% (n=52) of the patients were female, 63% (n=63) self-declared their skin color as white, 42% (n=42) belonged to CKD stage 3A, 90% (n=90) had Systemic Arterial Hypertension. 62.02% (n=366) of the drugs prescribed were from group C - Cardiovascular System. In 24% (n=18) there were type 1 DRPs when there is a need to add a drug to the patient's prescription. 382 drug interactions were found, 89.80% (n=343) of which were type C. In 44.88% (n=57) of the interventions, treatment monitoring was requested, especially the risk of rhabdomyolysis. In 39.75% (n=33) of the prescriptions for elderly patients, ASA was prescribed, which has High/Strong evidence for a potential risk of bleeding in this population. CONCLUSION: Through the technical analysis of the prescriptions of patients with CKD undergoing non-dialysis treatment, pharmaceutical care was provided through pharmaceutical interventions. |
